Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
Rohit Loomba, Kris V. Kowdley, José R Rodríguez-Medina, N K Kim, Alina Álvarez, Linda Morrow, Brenda I. Jeglinski, Alicia Clawson, Swapan K. Chowdhury, Gerard Bain, Tatjana Odrljin
Topics & Concepts
TolerabilityMedicinePlaceboClinical endpointDosingInternal medicineSteatohepatitisCohortRandomized controlled trialPhysical therapyAdverse effectFatty liverDiseasePathologyAlternative medicineFibroblast Growth Factor ResearchLiver Disease Diagnosis and TreatmentParathyroid Disorders and Treatments